Erratum: Novel gut-based pharmacology of metformin in patients with type 2 diabetes mellitus (PLoS ONE (2014) 9, 7 (e100778) DOI: 10.1371/journal.pone.0100778);Novel gut-based pharmacology of metformin in patients with type 2 diabetes mellitus

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Napolitano, Antonella ^a   Miller, Sam ^a   Nicholls, Andrew W ^a   Baker, David ^a   Van Horn, Stephanie ^b   Thomas, Elizabeth ^b   Rajpal, Deepak ^b   Spivak, Aaron ^b   Brown, James R ^b   Nunez, Derek J ^b  

^a GLAXOSMITHKLINE   (United Kingdom)

^b GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BILE ACID; CHOLIC ACID; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; METFORMIN; PEPTIDE YY; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL;

ACTINOBACTERIA; ADULT; AGED; ARTICLE; BILE ACID BLOOD LEVEL; BILE ACID METABOLISM; BLOOD SAMPLING; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG WITHDRAWAL; ENZYME ACTIVATION; FEMALE; FIRMICUTES; GLUCOSE BLOOD LEVEL; HORMONE BLOOD LEVEL; HORMONE RELEASE; HUMAN; INTESTINE FLORA; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ADOLESCENT; BLOOD; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; INTESTINE; METABOLISM; MICROBIOLOGY; MICROFLORA; MIDDLE AGED; MULTICENTER STUDY;

ADOLESCENT; ADULT; AGED; BILE ACIDS AND SALTS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INTESTINES; MALE; METFORMIN; MICROBIOTA; MIDDLE AGED; PEPTIDE YY;

EID: 84903759811     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0106594     Document Type: Erratum

References (56)

1. Standard of Medical Care in Diabetes -American Diabetes Association-(2013) Diabetes CareVol 36Suppl 1Jan 2013
2. Rena G, Pearson ER, Sakamoto K (2013) Molecular mechanism of action of metformin: old or new insights? Diabetologia. Sep 56(9):1898-906.
3. Zhou G, Myers R, Li Y, Chen Y, Shen X, et al. (2001) Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest;Oct; 108(8):1167-74
4. Giugliano D, De Rosa N, Di Maro G, Marfella R, Acampora R, et al. (1993) Metformin improves glucose, lipid metabolism, and reduces blood pressure in hypertensive, obese women. Diabetes Care;Oct; 16(10):1387-90
5. Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, et al. (2013) Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol MetabOct 22
6. Shields WW, Thompson KE, Grice GA, Harrison SA, Coyle WJ (2009) The Effect of Metformin and Standard Therapy versus Standard Therapy alone in Non diabetic Patients with Insulin Resistance and Nonalcoholic Steatohepatitis (NASH): A Pilot Trial. Therap Adv Gastroenterol;May; 2(3):157-63.
7. Quinn BJ, Kitagawa H, Memmott RM, Gills JJ, Dennis PA (2013) Repositioning Metformin for cancer prevention and treatment. Trends Endocrinol MetabSep;24(9)
8. Gui J, Liu Q, Feng L (2013) Metformin vs insulin in the management of gestational diabetes: a meta-analysis. PLoS One;May 27;8(5):e64585
9. Bonora E, Cigolini M, Bosello O, Zancanaro C, Capretti L, et al. (1984) Lack of effect of intravenous metformin on plasma concentrations of glucose, insulin, Cpeptide, glucagon and growth hormone in non-diabetic subjects. Curr Med Res Opin9(1):47-51. (Pubitemid 14139457)
10. Drucker DJ (2006) The biology of incretin hormones. Cell Metab 3: 153-165.
11. Tharakan G, Tan T, Bloom S (2011) Emerging therapies in the treatment of 'diabesity': beyond GLP-1. Trends Pharmacol Sci 32: 8-15.
12. Le Roux CW, Batterham RL, Aylwin SJ, Patterson M, Borg CM, et al. (2006) Attenuated peptide YY release in obese subjects is associated with reduced satiety. Endocrinology 147: 3-8. (Pubitemid 43004254)
13. Deacon CF (2004) Circulation and degradation of GIP and GLP-1. Horm Metab Res 36: 761-765.
14. Cuthbertson J, Patterson S, O'Harte FP, Bell PM (2009) Investigation of the effect of oral metformin on dipeptidylpeptidase-4 (DPP-4) activity in Type 2 diabetes. Diabet Med 26: 649-654.
15. Hinke SA, Kuhn-Wache K, Hoffmann T, Pederson RA, McIntosh CH, et al. (2002) Metformin effects on dipeptidylpeptidase IV degradation of glucagon-like peptide-1. Biochem Biophys Res Commun 291: 1302-1308 (Pubitemid 34694333)
16. Migoya EM, Bergeron R, Miller JL, Snyder RN, Tanen M, et al. (2010) Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1. Clin Pharmacol Ther 88: 801-808.
17. Green BD, Irwin N, Duffy NA, Gault VA, O'Harte FP, et al. (2006) Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1. Eur J Pharmacol 547: 192-199. (Pubitemid 44373906)
18. Lindsay JR, Duffy NA, McKillop AM, Ardill J, O'Harte FP, et al. (2005) Inhibition of dipeptidyl peptidase IV activity by oral metformin in Type 2 diabetes. Diabet Med 22: 654-657. (Pubitemid 40593146)
19. Vardarli I, Amdt E, Deacon CF, Holst JJ, Nauck MA (2014) Effect of Sitagliptin and Metformin treatment on Incretin hormone and insulin secretory responses to oral and "isoglycemic" intravenous glucose. Diabetes 63(2):663-74.
20. Thondam SK, Cross A, Cuthbertson DJ, Wilding JP, Daousi C (2012) Effects of chronic treatment with metformin on dipeptidyl peptidase-4 activity, glucagonlike peptide 1 and ghrelin in obese patients with Type 2 diabetes mellitus. Diabet Med 29: e205-e210.
21. Carter D, Howlett HC, Wiernsperger NF, Bailey CJ (2003) Differential effects of metformin on bile salt absorption from the jejunum and ileum. Diabetes Obes Metab 5: 120-125. (Pubitemid 36372504)
22. Mulherin AJ, Oh AH, Kim H, Grieco A, Lauffer LM, et al. (2011) Mechanisms underlying metformin-induced secretion of glucagon-like peptide-1 from the intestinal L cell. Endocrinology 152: 4610-4619.
23. Thomas C, Gioiello A, Noriega L, Strehle A, Oury J, et al. (2009) TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab 10: 167-177.
24. Tremaroli V, Bäckhed F (2012) Functional interactions between the gut microbiota and host metabolism. Nature Sep 13;489; (7415):242-9
25. Maurice CF, Haiser HJ, Turnbaugh PJ (2013) Xenobiotics shape the physiology and gene expression of the active human gut microbiome. Cell Jan 17;152; (1-2):39-50
26. Cabreiro F, Au C, Leung KY, Vergara-Irigaray N, Cochemé HM, et al. (2013) Metformin retards aging in C. elegans by altering microbial folate and methionine metabolism. Cell;Mar 28; 153(1):228-39
27. Greenway F, Wang S, Heiman M (2013) A novel cobiotic containing a prebiotic and an antioxidant augments the glucose control and gastrointestinal tolerability of metformin: a case report. Benef Microbes May; 17:1-4.
28. Stepensky D, Friedman M, Raz I, Hoffman (2002) A first-pass pharmacodynamic effect. Drug Metab Dispos;Aug; 30(8):861-8
29. International Conference on Harmonisation (1996) ICH Harmonised Tripartite Guideline. Guideline for Good Clinical Practice. Version 10.
30. Guiney WJ, Beaumont C, Thomas SR (2010) Use of the entero-test, a novel approach for the noninvasive capture of biliary metabolites in dogs. Drug Metab Dispos;May; 38(5):851-6
31. Caporaso JG, Kuczynski J, Stombaugh J, Bittinger K, Bushman FD, et al. (2010) QIIME allows analysis of high-throughput community sequencing data. Nat Methods; May; 7(5):335-6.
32. Haas BJ, Gevers D, Earl AM, Feldgarden M, Ward DV, et al. (2011) Chimeric 16S rRNA sequence formation and detection in Sanger and 454-pyrosequenced PCR amplicons. Genome Res;Mar; 21(3):494-504
33. Edgar RC (2010) Search and clustering orders of magnitude faster than BLAST. Bioinformatics;Oct 1; 26(19):2460-1
34. De Santis TZ, Hugenholtz P, Larsen N, Rojas M, Brodie EL, et al. (2006) Greengenes, a chimera-checked 16S rRNA gene database and workbench compatible with ARB. Appl Environ Microbiol;Jul; 72(7):5069-72
35. Navas-Molina JA, Peralta-Sánchez JM, González A, McMurdie PJ, Vázquez-Baeza Y, et al. (2013) Advancing our understanding of the human microbiome using QIIME. Methods Enzymol.531:371-444
36. Lozupone C, Lladser ME, Knights D, Stombaugh J, Knight R (2011) UniFrac: an effective distance metric for microbial community comparison. ISME J. Feb; 5(2):169-72
37. Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society, Series B 57 1:289-300.
38. Zhou G, Myers R, Li Y, Chen Y, Shen X, et al. (2001) Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest;Oct; 108(8):1167-74
39. Miller RA, Chu Q, Xie J, Foretz M, Viollet B, et al. (2013) Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP. Nature;Feb 14; 494(7436):256-60
40. Proctor WR, Bourdet DL, Thakker DR (2008) Mechanisms underlying saturable intestinal absorption of metformin. Drug Metab Dispos; Aug; 36(8):1650-8.
41. Gälman C, Angelin B, Rudling M (2005) Bile acid synthesis in humans has a rapid diurnal variation that is asynchronous with cholesterol synthesis. Gastroenterology;Nov; 129(5):1445-53.
42. Chen X, Lou G, Meng Z, Huang W (2011) TGR5: a novel target for weight maintenance and glucose metabolism. Exp Diabetes Res2011:853501
43. Holst JJ(2007) The physiology of glucagon-like peptide 1. Physiol Rev;Oct; 87(4):1409-39.
44. Bäckhed F, Ding H, Wang T, Hooper LV, Koh GY, et al. (2004) The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A. Nov 2;101(44):15718-23.
45. Karlsson F, Tremaroli V, Nielsen J, Bäckhed F (2013) Assessing the human gut microbiota in metabolic diseases. Diabetes;Oct; 62(10):3341-9
46. Maruo T, Sakamoto M, Ito C, Toda T, Benno Y (2008) Adlercreutzia equolifaciens gen. nov., sp. nov., an equol-producing bacterium isolated from human faeces, and emended description of the genus Eggerthella. Int J Syst Evol Microbiol May;58(Pt; 5):1221-7.
47. Toh H, Oshima K, Suzuki T, Hattori M, Morita H (2013) Complete Genome Sequence of the Equol-Producing Bacterium Adlercreutzia equolifaciens DSM 19450T. Genome Announc: Sep;24(9)e00742-13
48. Cho KW, Lee OH, Banz WJ, Moustaid-Moussa N, Shay NF, et al (2010) Daidzein and the daidzein metabolite, equol, enhance adipocyte differentiation and PPARgamma transcriptional activity. J Nutr Biochem;Sep; 21(9):841-7
49. Schwen RJ, Nguyen L, Jackson RL (2012) Elucidation of the metabolic pathway of S-equol in rat, monkey and man. Food Chem Toxicol;Jun; 50(6):2074-83
50. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, et al. (2006) An obesity-associated gut microbiome with increased capacity for energy harvest. Nature;Dec 21; 444(7122):1027-31
51. Turnbaugh PJ, Bäckhed F, Fulton L, Gordon JI (2008) Diet-induced obesity is linked to marked but reversible alterations in the mouse distal gut microbiome. Cell Host. Microbe3213223
52. Ley RE, Turnbaugh PJ, Klein S, Gordon JI (2006) Microbial ecology: human gut microbes associated with obesity. Nature44410221023
53. Cani PD, Delzenne NM (2011) The gut microbiome as therapeutic target. Pharmacol. Ther130202212
54. Cani PD, Osto M, Geurts L, Everard A (2012) Involvement of gut microbiota in the development of low-grade inflammation and type 2 diabetes associated with obesity. Gut Microbes3279288
55. Larsen N, Vogensen FK, van den Berg FW, Nielsen DS, Andreasen AS, et al. (2010) Gut microbiota in human adults with type 2 diabetes differs from nondiabetic adults. PLoS One;Feb 5; 5(2):e9085
56. Islam KB, Fukiya S, Hagio M, Fujii N, Ishizuka S, et al. (2011) Bile acid is a host factor that regulates the composition of the cecal microbiota in rats. Gastroenterology;Nov; 141(5):1773-81